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Abstract
Purpose of Review To describe in detail the clinical synopsis and pathophysiology of chronic non-bacterial osteomyelitis and
SAPHO syndrome.
Recent Findings Chronic non-bacterial osteomyelitis (CNO) has been identified as a disease entity for almost 50 years. This
inflammatory bone disorder is characterized by osteolytic as well as hyperostotic/osteosclerotic lesions. It is chronic in nature, but
it can present with episodic flairs and phases of remission, which have led to the denomination “chronic recurrent osteomyelitis”,
with its severe multifocal form “chronic recurrent multifocal osteomyelitis” (CRMO). For almost three decades, an infectious
aetiology had been considered, since especially Propionibacterium acnes had been isolated from bone lesions of individual
patients. However, this concept has been challenged since long-term antibiotic therapy did not alter the course of disease and
modern microbiological techniques (including PCR) failed to confirm bone infection as an underlying cause. Over recent years, a
profound dysregulation of cytokine expression profiles has been demonstrated in innate immune cells of CNO patients. A
hallmark of monocytes from CNO patients is the failure to produce immune regulatory cytokines interleukin-10 (IL-10) and
IL-19, which have been linked with genetic and epigenetic alterations. Subsequently, a significant upregulation of pro-inflam-
matory, NLRP3 inflammasome-dependent cytokines (IL-1β and TNF-α), has been demonstrated.
Summary The current knowledge on CNO, the underlying molecular pathophysiology, and modern imaging strategies are
summarized; differential diagnoses, treatment options, outcome measures, as well as quality of life studies are discussed.




CNO Chronic non-bacterial osteomyelitis
CRMO Chronic recurrent multifocal osteomyelitis
CT Computed tomography
DIRA Deficiency of interleukin-1 receptor antagonist
DMARD Disease-modifying anti-rheumatic drug
ERK Extracellular signal-regulated kinase
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FBLIM Filamin-binding LIM protein
G/M-
CSF
Granulocyte and monocyte colony stimulating
factor
HLA Human leucocyte antigen
IL Interleukin
IL1 RN Interleukin-1 receptor antagonist




MCP-1 Monocyte chemotactic protein 1 (also CCL2)
MIP Macrophage inflammatory protein
MRI Magnetic resonance imaging
MTX Methotrexate
NGS Next-generation sequencing
NLRP NACHT, LRR and PYD domains-containing
protein
NOMID Neonatal onset multisystemic inflammatory
syndrome
NSAIDS Non-steroidal anti-inflammatory drugs
PAPA Pyoderma gangrenosum and acne syndrome
PBMC Peripheral blood mononuclear cells
PCR Polymerase chain reaction
PSTPIP Proline-serine-threonine phosphatase-interacting
protein
RANK Receptor activator of nuclear factor-κB
RANKL Receptor activator of nuclear factor-κB ligand
SAPHO Synovitis acne pustulosis hyperostosis osteitis
syndrome
SPA Spondyloarthropathy
SFK src family tyrosine kinase family
TIRM Turbo inversion recovery measurement
TLR Toll-like receptor
TNF Tumour necrosis factor
TRAPS TNF receptor associated periodic syndrome
Introduction
In 1972, Gideon et al. first described an inflammatory bone
disease of subacute or chronic nature that affects bones with a
symmetrical and multifocal pattern [1]. Since then, a multi-
tude of descriptive terms has been used throughout different
medical subspecialties (orthopaedics, infectious diseases, pae-
diatric and adult rheumatology) to describe the disease. From
a current standpoint, chronic non-bacterial osteomyelitis
(CNO) seems to have become the consistent denomination
describing chronic bone inflammation independent of its dis-
tribution (unifocal vs. multifocal) or course (self-limited,
chronically active vs. recurrent) [2]. Subsequent consider-
ations in the 1980s identified chronic recurrent multifocal os-
teomyelitis (CRMO) as a severe form of CNO [3, 4].
In the past, a significant fraction of the patients received
antibiotic therapy in the initial treatment, when the diagnosis
was unclear, but also in part based on the reported occasional
isolation of Propionibacterium acnes, currently named
“Cutibacterium acnes”. However, starting in the 1990s, the
infectious nature of the disease was questioned, because of
increasing reports on sterile lesional biopsies and failure to
detect bacterial pathogens using molecular techniques, includ-
ing PCR [5].
More recently, the molecular basis of chronic inflammation
has been linked to a pro-inflammatory phenotype of mono-
cytes from CNO patients with increased expression of inflam-
matory interleukin (IL)-1β, IL-6 and TNF-α [6, 7], and re-
duced expression of immune regulatory IL-10 and IL-19 [8,
9••]. The resulting dysbalance between pro- and anti-
inflammatory pathways contributes to chronic tissue inflam-
mation, osteoclast activation, bone destruction, and in some
cases hyperostosis and sclerosis of bone. In addition, mast
cells have been identified to contribute to sterile inflammation
[10]. The molecular basis of CNO has also been analysed in
mouse models of chronic bone inflammation and in patients
with familial forms of CNO or (monogenic) autoinflammatory
bone disease with bone involvement. Significant knowledge
has been gained by the identification of gene mutations asso-
ciated with bone inflammation in mice (Pstpip2) and humans
(IL1RN), predominantly leading to NLRP3 inflammasome
activation, the production of pro-inflammatory cytokines IL-
1β, TNF-α and IL-18, and/or their reduced regulation [9••,
11, 12••].
Several authors have linked CNO to the concept of
spondyloarthropathies (SPA) [13]. However, in most co-
horts, HLA-B27 positivity ranges around frequencies in
the normal healthy population or is mildly elevated, and
male predominance is not present [14, 15••]. Further clas-
sical features of SPA, such as uveitis or urethritis, are
also not present [15••]. Clinical and pathophysiologic
proximity of CNO to the so-called SAPHO syndrome,
that usually affects adults, and overlap with psoriasis syn-
dromes have also been considered. The acronym SAPHO
stands for synovitis, acne, pustulosis, hyperostosis and
osteitis syndrome and was first described in 1987. Since
then, a considerable overlap between both entities,
SAPHO and CNO/CRMO, has been discussed, which is
mostly based on inflammatory cutaneous manifestations
in a subset of CNO patients [16–18, 19•• , 20].
Furthermore, also in adult SAPHO syndrome patients,
features of spondyloarthropathies are present. Of note,
the possible connection to SPA dominates the SAPHO
literature much more than in paediatric CNO [21].
Following the historic definition of systemic or organ spe-
cific inflammation in the absence of self-reactive lymphocytes
and high-titre autoantibodies, and the aforementioned central
involvement of innate immune mechanisms, CNO and
SAPHO have been classified as autoinflammatory diseases
[22, 23].
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Clinical Presentation and Laboratory Findings
Inflammatory bone lesions may be uni- or multifocal. With
the exception of the neurocranium, which is almost never
affected in CNO, inflammation can affect all sites of the skel-
eton [2]. Typical sites of inflammation include the
metaphyses/and epiphyses [24] of long bones of the extremi-
ties, the shoulder girdle including the clavicle and the sternum,
vertebral bodies, and (in rare cases) the mandible. From a
patients’ view, recurrent clinical symptoms, including local
swelling, pain and impairment of motion, are common com-
plaints. Imaging techniques suggest a primary chronic course
of periosteal and/or endosteal inflammation, osteitis and oste-
omyelitis. Clinically and also radiologically, arthritis of adja-
cent or remote joints may be present. In a few cohorts, a strong
clinical link towards SPA has been noted [13]. However, this
does not seem to be a general feature in children and adoles-
cents [15••].
Other organ systems may be involved as well. Up to 20%
of CNO patients develop skin manifestations, including
palmoplantar pustulosis, cystic acne and psoriasis [15••].
Chronic inflammatory bowel disease may be present in up to
10% of patients [25, 26]. Occasionally, hepatosplenomegaly
and lymph node enlargement are noted (up to 3% of patients).
Ocular or cardiac manifestations are generally rare. Uveitis or
episcleritis are no typical features of CNO [15••].
Laboratory tests usually show mild to moderate elevation
of inflammatory parameters, including CRP and ESR.
Preliminary reports promise potential for a set of serum pro-
teins to act as biomarkers for CNO. These include the pro-
inflammatory cytokine IL-6, the chemokine CCL-11/eotaxin
and others, and may help to differentiate CNO patients from
JIA and osteoarticular infections [27]. However, findings need
to be validated using alternative technologies in unrelated
multi-ethnic cohorts. Thus, and due to the limited general
availability, the clinical relevance of these findings is currently
limited. Based on register data from Europe, antinuclear anti-
bodies (ANA) are present in up to 39% of patients [15••].
However, the proportion of ANA-positive CNO patients in
large individual cohorts is usually much lower, ranging
around 10%. The number of lesions, the clinical picture, in-
flammatory laboratory parameters and the response to treat-
ment did not differ between ANA-positive and ANA-negative
patients [15••]. Thus, the relevance of ANA positivity in CNO
requires to be challenged and elucidated further. For now, no
conclusive clinical or laboratory autoimmune features have
been reported.
Taken together, in the absence of reliable and widely ac-
cepted laboratory tests, disease biomarkers or known genetic
causes, the definition and classification of CNO have to rely
on descriptive parameters. Several attempts have been made
to develop classification or diagnostic scores for CNO and to
separate its clinical picture/symptoms from acute bacterial
osteomyelitis or malignant bone disease. All include CNO
typical patterns of bone inflammation or monofocal bone dis-
ease with histological features resembling chronic inflamma-
tion in the absence of malignancy, the absence of other signs
severe systemic inflammation (such as fever, high CRP and/or
ESR), and chronic disease courses. As such, scores stay de-
scriptive and have not been validated prospectively and/or in
unrelated cohorts [28–30].
The Role of Histopathology and Microbiology
In patients who do not exhibit clinical symptoms and/or ra-
diographic findings conclusive for CNO, a biopsy of the/a
representative lesion is necessary. Tissue sections should be
read by pathologists experienced with bone malignancies and
CNO. First and foremost, malignancy (primary bone tumours,
metastases, lymphoma, etc.) and systemic disease
(Langerhans cell histiocytosis) require to be excluded. While
some features, such as coexistence of “acute” inflammatory
infiltrates (neutrophils, macrophages) with chronic inflamma-
tion (characterised by lymphocytes, plasma cells and mono-
cytes), and/or bone sclerosis, are more common in CNO than
other conditions, they are not specific. Chronic infections e.g.
may deliver similar histopathological patterns [5, 31, 32].
Thus, fresh (not paraffin embedded) bone tissue requires to
be tested for infectious agents. Microbial analyses should in-
clude long-term standard cultures, including the search for
mycobacteria. In addition, molecular microbial analysis of
biopsies, including universal microbial rRNA amplification,
mycobacteria search PCRs and possibly next-generation se-
quencing (NGS, where available and of interest), may be per-
formed. In most patients, non-suspicious microbial results will
be noted.
However, in individual cases, Propionibacterium/
Cutibacterium acnes may be present, which complicates the
diagnosis as theymay represent contamination [5, 33]. Thus, a
clinical dilemma exists as acute or chronic bacterial osteomy-
elitis may not exhibit high inflammatory parameters, especial-
ly when low-virulent strains of bacteria are present, such as
Propionibacteriae [34, 35].
The better the individual physician or clinical division is
acquainted with diagnosing CNO, the fewer biopsies will be
performed. During clinical work-up until infectious osteomy-
elitis is excluded, an initial antibiotic therapy may be reason-
able. However, if the clinical symptoms resemble those “typ-
ical” for CNO, antibiotic therapy may be omitted. Of note,
throughout international cohorts, antibiotic therapy has been
reported in as many as 38% of patients [15••].
In SAPHO, as in CNO, the fundamental clinical compo-
nent is inflammatory osteitis, which may result in hyperosto-
sis. Most frequently affected regions include the rib cage (ribs
and sternum), the spine and long bones of the extremities. This
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largely resembles the pattern in CNO [36]. Since arthritis/
synovitis and acne are included in the acronym, it appears that
SAPHO is closely related to childhood CNO, but covers bone
inflammation in the context of associated cutaneous manifes-
tations in a single individual. This association is certainly
present, but less common in classical paediatric CNO.
However, since in the overall adult population beyond
SAPHO patients, acne and pustulotic skin lesions are more
prevalent as compared with children and young adolescents,
a confounding factor may be present. Of note, one study re-
ported that up to 67% of bone biopsies from adult SAPHO
patients were positive for Propionibacterium acnes [37]. In
this context, it is interesting to note that Propionibacterium
acnes can trigger increased plasma levels of the chemokine
IL-8 and pro-inflammatory cytokines IL-18 and TNF-α. This
may be caused by stimulation of the Toll-like receptors (TLR)
2 and 4 by Propionibacterium acnes [38, 39]. However, pri-
mary antibiotic therapy for SAPHO syndrome seems only
effective as long as it is administered [37]. This led to the
conclusion that the presence of this bacterium at the site of
the lesion or in the skin might not be the only causative trigger
of the disease, but of relevance as it may amplify inflammation
in otherwise predisposed individuals. In addition, observed
effects of antimicrobials may also partially be explained by
anti-inflammatory effect of the drug studied (azithromycin).
With regard to HLA-B27, no consistent presence above the
expected regional frequencies was noted also in SAPHO [40].
In this respect, SAPHO mimics CNO. Though SAPHO syn-
drome is usually described in late adolescents and adults;
some cases of paediatric manifestations have been reported
[41]. Studies including both children and adults are rare.
Where comparisons are possible, adult patients sometimes
may have more skin involvement, but show a comparable
distribution of bone lesions. Lastly, treatment available ap-
pears less effective in adults as compared with children [42•,
15••].
Molecular Pathophysiology in Humans
and Mice
The molecular pathophysiology of “sporadic” CNO/CRMO
(not following Mendelian inheritance) is incompletely under-
stood. There is a significant need to analyse pathophysiolog-
ical pathways, since not only inflammatory components but
also potentially post-infectious reactive features have been
observed.
Monocytes isolated from peripheral blood of CNO/CRMO
patients fail to produce the immune regulatory cytokine IL-10
(and its homologue IL-19) in response to stimulation with
lipopolysaccharide (LPS). This has been linked with reduced
activation of mitogen-activated protein kinases (MAPK)
ERK1 and 2, which results in reduced activation of the
transcription factor signalling protein (SP-)1 and reduced
phosphorylation of histone H3 at serine position 10
(H3S10P). Reduced H3S10P results in epigenetic “closure”
of the IL10 promoter, which, in context with reduced avail-
ability of SP-1, translates to reduced IL-10 expression. At the
same time, pro-inflammatory IL-6, IL-20 and TNF-α are
expressed at increased levels. This may be secondary to in-
creased activation of the NLRP3 as absence of IL-10 primes
inflammasome assembly and subsequently may lead to re-
lease of IL-1β, which triggers TNF-α and IL-6 expression
[7, 20, 43]. Of note, in monocytes from CNO patients, DNA
methylation of inflammasome associated genes IL1, PYCARD
(encoding for the adaptor molecule ASC) and NLRP3 is re-
duced, resulting in increased gene expression [32]. However,
the exact chain of events causing the significant cytokine im-
balance in CNO has yet to be determined. In line with these
observations, tissue analyses of bone biopsies revealed a sig-
nificant deregulation/activation of the IL-1β axis [6, 9••].
Finally, these altered cytokine expression patterns may lead
to increased activation of osteoclasts via the RANK/RANK
ligand signalling pathways, directly affecting bone remodel-
ling [8]. Interestingly, comparable pathophysiological find-
ings have been seen in the serum of SAPHO patients [44].
Monogenetic systemic autoinflammatory disorders with
bone involvement partially resemble “sporadic” CNO, dem-
onstrating bone inflammation, osteolysis and hyperostosis.
CRMO, the severe form of CNO, shares clinical features with
chronic auto-inflammatory diseases, including deficiency of
the IL-1 receptor antagonist (DIRA), and pyogenic arthritis,
pyoderma gangrenosum and acne (PAPA) syndrome. Both
syndromes may show lesions of cartilage and osteolysis
[19]. In Majeed syndrome [45], an autosomal recessive inher-
itance has been documented with mutations in the lipin-2 gene
(LPIN2) [46]. In addition to multifocal bone lesions resem-
bling CNO, dyserythropoietic anaemia and pustulous derma-
tosis may be present.
Monogenic dominant mutations in the SH3 domain bind-
ing protein 2 (SH3BP2) can lead to a granulomatous bone
lesion of the lower jaw, named hereditary cherubism, partially
resembling paediatric CNO of the mandibles [19, 47].
Recently, Cox et al. reported homozygous mutations in the
filamin-binding domain of FBLIM1 as well as other types of
mutations in about 1% of their cohort patients, leading to bone
inflammation [48]. Of note, no other paediatric cohort has
been analysed genetically in a comparable detail. FBLIM1
analysis has been performed in an adult SAPHO patient co-
hort, but did not provide evidence of relevance in a German
cohort (Assmann G et al., 2020 submitted, in press, permis-
sion given in personal communication).
A point mutation in the FGR gene, encoding for the
Gardner-Rasheed feline sarcoma protein kinase, a member
of SFK family (src family tyrosine kinase), has been demon-
strated in Ali18 mice that resemble a model for sterile
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osteomyelitis. In a large cohort, approximately 13% of CNO
patients also carried rare exonic variants in this particular SFK
gene [49].
Further monogenic diseases resemble CNO in part: Bone
inflammation has been described in familial hyperphosphatemic
familial tumoral calcinosis affecting the DALNT3 gene [50], in
addition to primary hypertrophic osteoarthropathy, revealing
gene mutations in the prostaglandine metabolism and
hypophosphatasia with mutations in the tissue non-specific al-
kaline phosphatase gene (reviewed in [19]).
Besides the already mentioned Ali18 mice, further mouse
models affecting the proline-serine-threonine phosphatase
interacting protein 2 (Pstpip2) gene have been described.
The phenotype of these mice shows sterile inflammation of
bone, cartilage and skin. Inflammation is mediated by
chemokines and cytokines, including M-CSF, MIP-1α and
IL-1β. Particularly the Pstpip2 gene is tempting as a potential
target for CNO to be analysed, since on the other side muta-
tions in the PSTPIP1 gene are implicated in the pathogenesis
of another autoinflammatory syndrome, the PAPA syndrome.
However, no conclusivemutations inPSTPIP1 or 2 have been
revealed in sporadic CNO patient cohorts [51–53].
Though only few patients with suspected “sporadic” CNO
cohorts may indeed be affected by rare mutations in single
genes, keeping these differential diagnoses in mind is of rele-
vance, especially in very young children with CNO. Target-
directed treatments aiming for the correction of the biochem-
ical sequels may already be available for rare conditions, e.g.
enzyme replacement therapy in hypophosphatasia or recom-
binant IL-1 receptor antagonist replacement in DIRA. For a
(potentially incomplete) summary of relevant differential di-
agnoses, see Fig. 1.
Imaging Strategies
The diagnoses of exclusion CNO and SAPHO rely predomi-
nantly on imaging techniques. A number of differential diag-
noses remains to be considered as long as generally accepted
and validated diagnostic criteria including genetics and/or
biomarkers are missing. Over the past years, an international
expert group has been working towards the identification of
CNO-related symptoms and their classification, including im-
aging findings. This exercise aims at the harmonization of
diagnostic approaches and treatment in CNO [54, 55].
Diagnostic imaging frequently includes conventional X-
rays and/or regional magnetic resonance imaging (MRI) at
sites of pain. Occasionally, computed tomography (CT) is
used if MRI is unavailable or does not deliver sufficient detail
in depicting the bony structure. In children, CT imaging
should be avoided. Whole body imaging is a central imaging
tool for the diagnosis of CNO and is performed to monitor for
additional sites of bone inflammation, especially in the verte-
bral column. Whole body (WB-)MRI is the gold standard to
screen for additional, potentially clinically silent lesions. In
the past, 99mtechnetium bone scintigraphy was used, but
should be considered obsolete and only be used if whole body
MRI/MRI is not available [24, 56].
Initially during clinical care, X-ray images are frequently
taken to exclude differential diagnoses e.g. bone fractures and
may (but certainly do not have to) showCNO-associated chang-
es. Conventional X-rays may already show osteolytic lesions or
hyperostotic features. Especially long bones of the extremities
are prone to such changes, which appear later in the course of
disease. Fractures of long bones are very rare. However, frac-
tures can occur in vertebrae of up to 10% of CNO patients [57].
Conventional X-rays may also be normal and usually cannot
distinguish CNO from the features of malignant bone diseases,
such as osteosarcoma or Ewing’s sarcoma.
Currently, MRI studies are the imaging gold standard in
CNO. Usually, at the time of diagnosis, regional MRIs are
performed and can help to diagnose CNO and exclude differ-
ential diagnosis [58]. In the authors’ institutions, regional
MRIs using TIRM (or STIR) sequences are used to localize
and assess the extent of inflammation, followed by native T1
sequences and (not always) contrast-enhanced T1-weighted
sequences with fat saturation to assess regional changes and
surrounding tissue involvement. At diagnosis, WB-MRI pro-
vides information on the distribution of bone lesions, soft





















Fig. 1 Differential diagnosis of chronic non-bacterial osteomyelitis in childhood
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involvement which may be present in malignant disease (such
as neuroblastoma). Noteworthy, based on growing experi-
ence, the use of MRI contrast media can be omitted during
follow-up investigations or if initial WB-MRIs at diagnosis
show CNO typical multifocal patterns [59] (Fig. 2).
Especially during long-term follow-up, repetitive (WB or re-
gional) MRI can be used for assessing the extent and distribu-
tion of lesions and, thus, severity of CNO in order to guide
treatment.
Though it should not be used for the differential diagnosis of
CNO in children, because of radiation and general superiority
of MRI, CT may be helpful in rare occasions to exclude differ-
ential diagnoses (e.g. detection of the nidus in osteoid osteoma
or osteoblastoma) [60]. Based on reports in the literature, for
diagnosing and management of SAPHO syndrome in adults,
CT appears to be of higher diagnostic relevance in clinical
practise when compared with paediatric CNO [39, 42•].
Treatment, Monitoring and Treat-to-Target
Protocols
CNO Treatment
Currently, no treatments are approved for the use in CNO.
However, there is general consensus that CNO patients benefit
Fig. 2 Whole body MRI of CNO. Whole body MRI using turbo
inversion recovery measurement (TIRM) (a) of a 12-year-old male
patient exhibiting symmetrical inflammatory bone lesions of the distal
radius (b), distal tibiae (e), iliac bones (c), the sacral bone (d) and
metatarsal bones (f). Knees were not affected (g)
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from anti-inflammatory therapies using non-steroidal anti-in-
flammatory drugs. If NSAIDS are administered on a regular
and controlled basis, a significant portion of patients (up to
70%) may reach a symptom-free state after 18 months [2].
Based on the current pathophysiological understanding of
CNO, NSAIDs may (at least partially) correct increased oste-
oclast activity through the reduction of prostaglandin produc-
tion (inhibition of cyclooxygenase enzymes). Prostaglandins
are essential for osteoclast differentiation and activation.
Furthermore, NSAIDs affect pain processing which explains
their more immediate analgesic effects [8]. In order to estimate
their overall effectiveness, a recent long-term retrospective
study demonstrated that 50% of NSAID-treated CNO patients
may develop flares after a median of 29 months [61]. In cases
refractory to NSAID treatment, patients may benefit from
short courses of corticosteroid therapy, in addition to NSAIDs.
Defining the therapeutic target together with patients and
families is of particular importance in CNO. In light of this,
even in patients in “full clinical remission”, MRI may still
document altered and hyperintense bone signals (“active bone
lesions”). To address this, a disease activity score (ped CNO-
score) has been developed that includes the number of bone
lesions, in addition to inflammatory lab parameters [62]. As
long as no structural damage, especially to the spine, is noted
and the patient is improving by clinical means, non-steroidal
anti-inflammatory medication may serve as the only medica-
tion used, especially if the “target” is a pain-free condition. In
patients with a multifocal pattern and/or vertebral structural
involvement, or patients experiencing relapses or insufficient
response to NSAID, the “target” should focus not only pain
control and improvement of impairments; the “target” consid-
erations should also include a lesion-free MRI.
Classical disease-modifying antirheumatic drugs
(DMARDs), such as sulfasalazine or methotrexate (MTX),
may be used to reach this target as well as cytokine blocking
strategies/biologic DMARDs, usually TNF-α blocking medi-
cations, or bisphosphonates [2, 8, 61, 63]. Based on the
abovementioned pathophysiological models, corticosteroids
may (similar to NSAIDs, but through inhibition of phospho-
lipase A) inhibit osteoclast differentiation and activation.
Furthermore, corticosteroids reduce the expression of NFkB-
dependent pro-inflammatory cytokine expression while in-
creasing anti-inflammatory cytokine expression (including
IL-10) [8]. In the authors’ institutions, corticosteroids are usu-
ally used in short “oral bursts” of 5–10 days to induce rapid
control of bone inflammation. Some authors use corticoste-
roids for several weeks to induce remission and cover until
classical DMARDs are developing full efficacy [54].
Cytokine blocking strategies in CNO usually consist of TNF
inhibitors, which (at least partially) correct the imbalance in
pro- vs. anti-inflammatory cytokine expression [61] and ap-
pear effective in patients who failed to respond to the afore-
mentioned treatment options. Vertebral involvement without
structural damage may be subjected to TNF inhibition. Based
on the current pathophysiological understanding, IL-6 or IL-1
blocking agents also promise therapeutic potential. Individual
cases reported in the literature suggest efficacy of treatment
with recombinant IL-1 receptor antagonist (anakinra) in some
cases [64].
In cases of spinal bone affection/destruction and/or severe
multifocal CNO, long-term sequelae including scoliosis may
result. Thus, bisphosphonates have been suggested in this type
of manifestation and documented to be a good treatment op-
tion in several cohorts [4] [15••, 54, 65–67]. Furthermore,
bisphosphonates are an alternative to biologic DMARDs in
otherwise treatment refractory cases or individuals with in-
volvement of the vertebral spine or mandible. Some authors
claim that they should be used first line for vertebral involve-
ment with structural damage (fractures) [8, 54, 61].
Bisphosphonates inhibit osteoclast activity and may
(partially) correct the imbalance between pro- and anti-
inflammatory cytokines in a yet to be determined manner
(reviewed in [8]).
Because, with the exception of one controlled pro-
spective follow-up study using NSAID, no prospectively
collected data exists investigating treatment responses in
CNO [62], an international initiative (led by the North
American CARRA group) provided consensus diagnos-
tic and treatment plans for CNO patients who fail to
respond to NSAID treatment or have vertebral involve-
ment [54]. The “target” of therapeutic strategies should
be based on the consensus with the patients and parents.
Ideally, the goal may be a symptom-free state in addi-
tion to the reduction of signs of inflammation or remis-
sion on WB-MRI imaging. However, this latter goal
usually comes along with a necessary long-term treat-
ment approach, especially if MRI changes are still pres-
ent, but the patient may not experience complaints any
more. Acceptance of further therapy might be limited in
this constellation [54, 62]. The mentioned international
initiative aims at homogenised diagnostic approaches
and treatment protocols, and will prospectively collect
treatment response data [54] (Fig. 3).
SAPHO Treatment
Evidence-based data on SAPHO syndrome are in urgent need
as randomized controlled trials also do not exist. Non-
steroidal drugs are generally used as first-line treatment with
limited effectiveness as compared with paediatric CNO.
Taking into account the potential disease amplifying role of
bacteria, e.g. Cutibacterium acnes, some authors suggest ben-
eficial effects in the administration of antibiotics (such as
azithromycin, doxycycline, clindamycin and sulfamethoxa-
zole/trimethoprim) [37, 68, 69]. Systemic or intra-articular
corticosteroids may have positive effects, but their use is
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limited due to side effects and limited long-term efficacy [70,
71]. Bisphosphonates are used regularly, especially if the
spine is affected [40, 72]. A not randomized study recently
showed significant improvement of symptoms in response to
treatment with pamidronate for spinal bone marrow edema,
leading to the authors’ recommendation to use pamidronate as
first-line treatment especially in cases with spinal involvement
[73].
Classical DMARDs, such as methotrexate or sulfasalazine,
are widely used in SAPHO with inconclusive results [40]. In
otherwise treatment refractory cases, biologic DMARDs can
be introduced [74]. Several biological DMARDs have been
described with beneficial outcome [40]. In addition to anti-
TNF agents that have positive effects on musculoskeletal
manifestations and partly on the skin, other cytokine-
blockers are used. Daoussis et al systematically reviewed pub-
lished case studies and case reports focussing on biologic
DMARD treatment [75]. Preliminary reports suggest IL-1
blockade with anakinra to have beneficial effects in osteitis
and arthritis [76], but variable effects on mucocutaneous in-
volvement [77]. Due to its successful use in psoriasis treat-
ment, secukinumab, an IL-17A neutralizing antibody, was
used in SAPHO patients mainly affected by skin manifesta-
tions, but also positive effect on osteitis was seen. Thus, the
use of IL-17-blockade may be another therapeutic option in
otherwise refractory cases [75]. Individual case reports exist
on successful treatment of SAPHO with apremilast, a PDE4-
inhibitor [78], or the JAK inhibitor tofacitinib [79, 80].
Disease Outcomes and Quality-of-Life
Long-term experience strongly suggests that using anti-
inflammatory medication “on demand” may not improve the
long-term outcome of CNO. Data on controlled treatment du-
ration is limited: Patients with multifocal disease have been
reported to reach remission after 1.5 years [2]. However, up to
50% of patients may relapse after approximately 2.5 years,
demonstrating the chronic nature of bone inflammation in
CNO [61]. Generally, the prognosis of CNO is considered
reasonably good, if an anti-inflammatory medication is con-
sequently administered [61, 62]. In case of an insufficient
treatment response to NSAIDs or with vertebral involvement,
conventional or biological disease-modifying agents or
bisphosphonates should be considered. In the absence of li-
censed treatment options and/or randomised controlled trials,
treatment should be planned following the aforementioned
international consensus protocols [54]. Though patients expe-
rience significant pain, negatively affecting their quality-of-
live and/or psychosocial development, long-term quality-of-
life and disease outcomes in CNO patients have been reported
to be good when treated appropriately [81].
CNO/CRMO without spinal manifestation 
Treatment Plan B: 
Biological DMARDs 






Treatment Plan C: 
Bisphosphonates 














Remission No Remission 
CNO/CRMO with spinal manifestation  
and/or structural bone lesion 
Fig. 3 Proposed treat-to-target protocol for childhood CNO
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Conclusions
CNO/CRMOand SAPHO are autoinflammatory conditions with
a strong involvement of cytokine dysregulation. While paediatric
CNO is primarily associated with increased activation of innate
immunemechanisms and responds to blockade of these, SAPHO
patients respond toblockadeof IL-17A,aprimarilyTlymphocyte-
derived cytokine. This may support variable pathomechanisms in
adult SAPHO patients as compared with paediatric CNO with
adaptive immune cells playing a more pronounced role in
SAPHO syndrome. While this is not scientifically proven, T cell
involvement in SAPHOmay reflect secondary activation of adap-
tive immunemechanisms as (at least some) SAPHOpatientsmay
have experienced “isolated”CNO before the onset of skin symp-
toms. Prospective collection of treatment response data alongside
biosamples formolecular studiesmayresult inpatient stratification
and individualised treatments. This requires national and interna-
tional collaborations such as initiated by the PRES Eurofever ini-
tiative [15••] or theNorthAmericanCARRAgroup in association
with many international partners [54].
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